Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. Juni 2011 08:35 ET | Quelle: Marina Biotech, Inc.

Marina Biotech Completes Dosing of First Cohort in the Phase 1b/2a START-FAP Clinical Trial of CEQ508

BOTHELL, WA--(Marketwire - Jun 9, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced the completion of dosing for Cohort 1 in...
24. Mai 2011 08:35 ET | Quelle: Marina Biotech, Inc.

Marina Biotech Demonstrates That Its Proprietary Conformationally Restricted Nucleotides (CRN) Technology Is Highly Active as a microRNA Antagonist

BOTHELL, WA--(Marketwire - May 24, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNA-based drug discovery and development company, reported data demonstrating increased hybridization...
17. Mai 2011 08:15 ET | Quelle: Marina Biotech, Inc.

Marina Biotech Announces Pricing of Public Offering

BOTHELL, WA--(Marketwire - May 17, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced the pricing of an underwritten public...
16. Mai 2011 16:05 ET | Quelle: Marina Biotech, Inc.

Marina Biotech Announces Proposed Public Offering of Common Stock and Warrants

BOTHELL, WA--(Marketwire - May 16, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that it intends to offer and sell common...
16. Mai 2011 13:00 ET | Quelle: Marina Biotech, Inc.

Marina Biotech, Inc. Announces First Quarter 2011 Financial Results

BOTHELL, WA--(Marketwire - May 16, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported financial results for the first quarter...
09. Mai 2011 09:00 ET | Quelle: Marina Biotech, Inc.

Marina Biotech, Inc. to Report First Quarter Results on May 16, 2011 at 4:30 p.m. Eastern Time

BOTHELL, WA--(Marketwire - May 9, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that it will host a conference call with...
26. April 2011 08:30 ET | Quelle: Marina Biotech, Inc.

Marina Biotech Publishes Pre-Clinical Research on the Application of DiLA2 Delivery Technology for Systemic Delivery of siRNAs

BOTHELL, WA--(Marketwire - Apr 26, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, announced today the publication of data highlighting the...
20. April 2011 08:59 ET | Quelle: Marina Biotech, Inc.

Marina Biotech Completes Enrollment of Its First Cohort in the START-FAP Clinical Trial of CEQ508

BOTHELL, WA--(Marketwire - Apr 20, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced the completion of enrollment in the first...
12. April 2011 08:30 ET | Quelle: Marina Biotech, Inc.

Marina Biotech Announces Patent Allowance for Its Proprietary Nucleic Acid Delivery Technology

BOTHELL, WA--(Marketwire - Apr 12, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the Canadian Patent Office has issued...
07. April 2011 08:30 ET | Quelle: Marina Biotech, Inc.

Marina Biotech Initiates Dosing in the Phase 1b/2a START-FAP Clinical Trial of CEQ508

BOTHELL, WA--(Marketwire - April 7, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced the initiation of patient dosing in the...

Vorherige Seite